Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCTon survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis onWPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages.

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome / Alessandrino, E. P.; Porta, M. G. D.; Malcovati, L.; Jackson, C. H.; Pascutto, C.; Bacigalupo, A.; van Lint, M. T.; Falda, M.; Bernardi, M.; Onida, F.; Guidi, S.; Iori, A. P.; Cerretti, R.; Marenco, P.; Pioltelli, P.; Angelucci, E.; Oneto, R.; Ripamonti, F.; Rambaldi, A.; Bosi, A.; Cazzola, M.; Levis, A.; Bandini, G.; Casini, M.; Rossi, G.; Baronciani, D.; La Nasa, G.; Milone, G.; Mordini, N.; Corradini, P.; Milani, R.; Morra, E.; Lambertenghi Deliliers, G.; Ciceri, F.; Castagna, L.; Narni, F.; Selleri, C.; Scime, R.; Iannitto, E.; Musso, M.; Locatelli, F.; Zecca, M.; Martelli, F.; Visani, G.; Di Bartolomeo, P.; Cavanna, L.; Papineschi, F.; Messina, G.; Merli, F.; Ior, A. P.; Foa, R.; Locasciulli, A.; Majolino, I.; Chiusolo, P.; Leone, G.; Arcese, W.; Carella, A. M.; Cascavilla, N.; Mazza, P.; Bruno, B.; Boccadoro, M.; Fanin, R.; Cerno, M.; Raimondi, R.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 88:7(2013), pp. 581-588. [10.1002/ajh.23458]

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Rossi G.;Milani R.;Ciceri F.;
2013-01-01

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCTon survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis onWPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages.
File in questo prodotto:
File Dimensione Formato  
American J Hematol - 2013 - Alessandrino - Optimal timing of allogeneic hematopoietic stem cell transplantation in patients.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 504.02 kB
Formato Adobe PDF
504.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/138398
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 43
social impact